Everest Organics Limited today announced submission of the first US.DMF for Esomeprazole Magnesium API.
Ever since the successful USFDA approval received for its manufacturing facility, the Company has placed a separate focus to strengthen its presence in regulatory markets. With the first filing of US-DMF for Esomeprazole Magnesium, the Company focuses to increase presence in the US market for substantial revenue generation.
Commenting on the important development, Dr. S. K. Sirisha, Director & Head Regulatory Affairs, Everest Organics Ltd. said, "I am very pleased with the efforts of the entire R&D and Regulatory team of Everest Organics Ltd., for the team work, towards making the filing a success. As stated earlier, the next 3 years focus of the Company is to make at least 30% to 40% of its Top Line to be contributed by sales to regulated markets which will result in both top line and bottom line improvement, thus creating value for the company to be competitive in the Global arena".
Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs.223.9 as compared to the previous close of Rs. 211.3. The total number of shares traded during the day was 4191 in over 113 trades.
The stock hit an intraday high of Rs. 229.5 and intraday low of 210. The net turnover during the day was Rs. 929324.